Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
- Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first - in-class fixed - dose combinations. - ASC36o, a once-weekly oral amylin receptor peptide agonist, is the most advanced drug...